Skip to main content
PLEASE NOTE: For everyone’s safety, Fasken requires anyone on-site at our Canadian offices to provide proof of full vaccination against COVID-19. This applies to lawyers, staff, clients, service providers and other visitors.
Client Work

Sophiris closes US $65 million public offering

Reading Time 1 minute read Subscribe

​Sophiris Bio

On August 23, 2013, Sophiris Bio Inc. (Sophiris) closed its initial US public offering (the Offering). Sophiris issued 13,000,000 common shares at a price of US $5.00 per share for aggregate gross proceeds of US $65 million. In connection with the Offering, Sophiris’ common shares were listed on NASDAQ. Citigroup and Leerink Swann, acted as joint book-running managers, with Stifel and Lazard Capital Markets acting as co-managers (collectively, the Underwriters). Sophiris Bio is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Fasken Martineau was counsel to Sophiris Bio with a team which included Iain Mant, Amanda Robinson, Michael Hobkirk (M&A) and Frank Schober (tax).


    Receive email updates from our team